Technical Data
N5385-01A
NRAS (Neuroblastoma RAS Viral (v-ras) Oncogene Homolog, N-Ras, ALPS4, AV095280, GTPase NRas, HRAS1, N-Ras Protein Part 4, NRAS1, OTTHUMP00000013879, OTTMUSP00000023521, Transforming Protein N-Ras, v-Ras Neuroblastoma RAS Viral Oncogene Homolog)
Description:
This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated to a GTP-bound form by a GTPase activating protein and inactivated to a GDP-bound form by a guanine nucleotide-exchange factor. Defects in this gene are a cause of juvenile myelomonocytic leukemia (JMML).

Applications:
Suitable for use in ELISA, Immunohistochemistry and Western Blot. Other Applications not tested.

Recommended Dilutions:
ELISA: 1:32,000
Western Blot: 0.01-0.03ug/ml
Immunohistochemistry (Paraffin): 2-3ug/ml Requires HEIR using citrate buffer pH6.0
Optimal dilutions to be determined by the researcher.

Positive Control:
Human lysates of cell line A431

Blocking Peptide:
N5385-01A1

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20°C. Aliquots are stable for at least 12 monthsat -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide, C-RMKKLNSSDDGTQ, from the internal region of human NRAS.
Purity:
Purified by affinity chromatography.
Form
Supplied as a liquid in Tris, pH 7.3, 0.5% BSA, 0.02% sodium azide.
Specificity:
Recognizes human NRAS at ~21kD. Species sequence homology: mouse, rat, canine.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee- Taylor J, Conway K. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):991-7.